For the Inventor, By the Inventor

Enter assignee name

Thousand Oaks, CA, United States of America

Immunex Corporation

USPTO Granted Patents = 451

% Expired Patents = 32.8

CIPO Patents = 13

EPO Patents = 25

Trademarks = 12

Forward Citations = 9,717

Loading Chart...

Loading Chart...

193 inventors (with patents filed for the assignee):

John Ernest Sims (60 out of 66 patents)

Dirk M Anderson (50 out of 53 patents)

David J Cosman (41 out of 43 patents)

4. Douglas Pat Cerretti (38 out of 45 patents)

5. Raymond G Goodwin (34 out of 39 patents)

6. Richard Jeffrey Armitage (33 out of 39 patents)

7. Carl J March (32 out of 32 patents)

8. Melanie K Spriggs (32 out of 33 patents)

9. M Patricia Beckmann (32 out of 35 patents)

10. William Christian Fanslow, Iii (28 out of 36 patents)

11. Stewart D Lyman (25 out of 28 patents)

12. Craig A Smith (24 out of 32 patents)

13. Bruce A Mosley (19 out of 19 patents)

14. Peter Robert Baum (19 out of 31 patents)

15. Kenneth H Grabstein (18 out of 37 patents)

Core Competencies:

Anti-human VISTA Antibodies

Interleukin-4 Receptor

Tumor Necrosis Factor Receptor

Immunosuppression

TSLP Activity Inhibition

RANK Ligand Polypeptides

Blocking Antibodies

Leukocyte Immunoglobulin-like Receptors

C-type Lectin Polypeptides

TRAIL Polypeptides

Osteoclast Activity

Inflammatory Disorders

451 patents: Sort by Forward Citations

1. 12139532 - Anti-human vista antibodies and use thereof (2024-11-12),

2. 11649283 - Anti-human vista antibodies and use thereof (2023-05-16),

3. 11603403 - Anti-human vista antibodies and use thereof (2023-03-14),

4. 11603402 - Anti-human vista antibodies and use thereof (2023-03-14),

5. 11596689 - Methods of immunosuppression comprising administering an anti-CD154 antibody (2023-03-07),

6. 11525000 - Anti-human VISTA antibodies and use thereof (2022-12-13),

7. 11104714 - Compositions comprising a P75 tumor necrosis factor receptor/Ig fusion protein (2021-08-31),

8. 10874738 - Anti-CD154 antibody having improved binding, functional and safety characteristics (2020-12-29),

9. 10370455 - Identification of VSIG8 as the putative VISTA receptor (V-R) and use thereof to produce VISTA/VSIG8 agonists and antagonists (2019-08-06),

10. 9587026 - Anti-interleukin-4 receptor antibodies (2017-03-07),

11. 9518111 - Compositions comprising a p75 tumor necrosis factor receptor/Ig fusion protein (2016-12-13),

12. 9346870 - Antibodies that inhibit TSLP activity (2016-05-24),

13. 9045558 - Nucleic acids encoding modified human thymic stromal lymphopoietin (2015-06-02),

14. 8828947 - Polypeptide formulation (2014-09-09),

15. 8722631 - Soluble tumor necrosis factor receptor treatment of medical disorders (2014-05-13),

Company Overview

Immunex Corporation, based in Thousand Oaks, California, specializes in the development of innovative immunotherapy antibodies aimed at treating various diseases. The company focuses on advanced therapeutic solutions, particularly in the realm of immunosuppression and immune modulation. Its core technologies include anti-human VISTA antibodies, interleukin-4 receptor targeting, and tumor necrosis factor receptor modulation. Immunex is dedicated to enhancing patient outcomes through cutting-edge research in immunology and related fields.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

451 Patents

#2 in Thousand Oaks, CA

#231 in California

#1,064 in US

#2,117 in the World

Thousand Oaks, CA, United States of America

Immunex Corporation

Forward Citations = 9,717

193 inventors:

John Ernest Sims (60 out of 66 patents)

Dirk M Anderson (50 out of 53 patents)

David J Cosman (41 out of 43 patents)

4. Douglas Pat Cerretti (38 out of 45 patents)

5. Raymond G Goodwin (34 out of 39 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Immunex Corporation. Retrieved from https://idiyas.com/company/immunex

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…